Clinical Trial Update: A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

View source ↗

Summary

Clinical trial update describes an exploratory biomarker study evaluating combined PD-1/PD-L1 and CTLA-4 blockade plus anti-angiogenic therapy in MSS metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Msi-h Solid Tumors

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy | Status: RECRUITING